<DOC>
	<DOC>NCT01053715</DOC>
	<brief_summary>The aim of this study is to describe Health Related Quality of Life (HRQoL) in adolescents and adults with Hemophilia A treated prophylactically or on-demand with Helixate NexGen. The study will also assess the kinds of determinants, including key transitional life events, that might impact HRQoL in this patient population.</brief_summary>
	<brief_title>Quality of Life Study of Helixate NexGen</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Haemophilia A patient Severely (&lt;1%) and moderately (15%) affected On treatment with Helixate NexGen Ability to read and understand study materials (patient information and data protection form, patientrelated questionnaires) Signed data protection form; if patient is &lt;18 years of age, legal guardian must also give written consent by signing the data protection form Presence of inhibitors Abuse of recreational drugs or alcohol interfering with the everydaylife in the opinion of the physician Advanced stage human immunodeficiency virus (HIV) infection (CD4 cell counts &lt;200/cmm, multidrug resistance, presence of AIDS related signs or symptoms) Symptomatic liver disease (cirrhosis, ascites, esophageal varices) Concomitant or planned interferon therapy Malignancies on or off treatment</criteria>
	<gender>Male</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>Quality of Life</keyword>
</DOC>